Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease

Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease is a complete reference containing updated information on the advantages and disadvantages of dual antiplatelet therapy, its duration, composition and anticipated changes. The basis for DAPT in arterial disease is discussed, allowing readers to understand platelet physiology and its relevance to ischemic events. Data on shorter than usual duration of DAPT, and on extended therapy beyond the recommendation of current guidelines is presented in great detail, summarizing a large body of evidence into concrete, relevant recommendation that is readily adaptable by practicing clinicians.

A clinically relevant and updated compendium of data pertaining to this field is also presented, as well as the anticipated trends and innovations likely to occur in the next 3-5 years.

• Summarizes a large body of evidence into concrete, relevant recommendations that is readily adapted by practicing clinicians
• Explores the current status of DAPT, controversial topics, and future developments and trends in this field
• Edited and contributed by renowned cardiologists in the field

Table of Contents

1. Platelets and arterial disease – initiation, progression and destabilization of atherosclerotic vascular disease
2. Platelet physiology and pharmacology – relevant considerations for patient care
3. The development of dual antiplatelet therapy – physiologic and clinical implications of multiple pathway inhibition of platelet function
4. Acute coronary syndromes and percutaneous coronary intervention – current recommendations for dual antiplatelet therapy. Are guidelines reflecting the data?
5. Peripheral arterial disease – a different kind of arterial disease? The role of antiplatelet therapy in prevention and treatment of limb ischemia
6. Cerebrovascular disease – what is the role of DAPT for prevention and treatment of ischemic stroke?
7. Competing risks in DAPT duration of therapy – the case for shorter treatment
8. DAPT may prevent coronary ischemic events beyond one year – the case for extended DAPT treatment
9. How to integrate risk of bleeding and ischemic events in clinical medicine? The role of risk scores
10. Moving from DAPT to monotherapy based on P2Y12 receptor blockade – why it could be a novel paradigm?
11. The conundrum of simultaneous antiplatelet and antithrombotic therapy – how to resolve it?
12. A look to the future

REVIEW-URI